Pocketbook guidelines
For management of diabetes in childhood & adolescence in under-resourced countries
The information in these guidelines is aimed to assist healthcare professionals in less-resourced countries to optimise the clinical care of children and young adults with diabetes while considering resource- and cost-related issues.
Second edition 2017 with expanded Nutrition and Pregnancy chapters and various other updates.
The pocketbook is available to download in these languages:
Basaglar Switch Guidelines
Glargine (Basaglar) and Lispro (Humalog) Switch Guidelines
The information in these guidelines aim to assist healthcare professionals working in under-resourced countries with transitioning children and young adults with diabetes from Premixed (e.g. Humulin 30/70) or intermediate acting (i.e. NPH) and short acting human insulin (e.g. Humulin R), to a basal-bolus regimen of long-acting glargine (Basaglar) insulin and rapid-acting insulin lispro (Humalog).
The following guide, an Excel insulin switching dose calculation sheet, a 'cheat sheet' guide, key points for healthcare professionals, as well as key points for families and youth are downloadable in these languages:
Glargine (Basaglar) and short acting human insulin (Humulin R) Switch Guidelines
The information in these guidelines aim to assist healthcare professionals working in under-resourced countries with transitioning children and young adults with diabetes from Premixed or intermediate acting and short acting human insulin to a basal-bolus regimen of long-acting analog glargine (Basaglar) and short acting regular human insulin (Humulin R).
The following guide, an Excel insulin switching dose calculation sheet and a 'cheat sheet' guide for healthcare professionals, as well as an educational handout for families and youth are downloadable in these languages:
Introduction de la glargine (Basaglar) et à l'insuline humaine d’action rapide (Humulin R)
Les informations contenues dans ces directives visent à aider les professionnels de santé travaillant dans des pays aux ressources limitées à faire passer les enfants et les jeunes adultes diabétiques d’un traitement à base d’insuline humaine prémélangée ou à action intermédiaire et à action rapide à un traitement basal-bolus à base d’analogue de glargine à action prolongée (Basaglar) et d’insuline humaine régulière d’action rapide (Humulin R).
Introduction de la glargine (Basaglar) et analogue d'insuline à action rapide (Humalog)
Bientôt disponible
Type 1 diabetes warning signs - posters
To help prevent Diabetic Ketoacidosis
These posters aim to increase awareness of the signs and symptoms of type 1 diabetes so the right diagnosis and swift treatment can be initiated to prevent life-threatening Diabetic Ketoacidosis (DKA).
These posters can be displayed in hospitals, community centres, churches or mosques, and other common areas.
Wall charts
Camp guidelines
Guidelines for conducting diabetes camp activities in a less-resourced country
LFAC collaborated with the Diabetes and Education Camping Association (DECA) to develop these guidelines.
Camps offer a unique peer-support opportunity for young people and caregivers, and can enhance diabetes management skills, confidence, and resilience in a fun and safe environment.
The guidelines are available to download in:
